862
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Antibacterial Effect of Fermented Milk Containing Bifidobacterium breve, Bifidobacterium bifidum and Lactobacillus acidophilus against Indigenous Escherichia coli Infection in Mice

, , , &
Pages 16-24 | Published online: 11 Jul 2009

References

  • Glucksberg H, Cheever MA, Farewell VT, Sale WE, Thomas ED. High dose combination chemotherapy for acute non-lymphoblastic leukemia in adults. Cancer 1981; 48: 1073–81.
  • Keating MJ, Smith TL, McCredie KB, Body GP, Hersh EM, Gutterman JU, et al. A 4-year experience with anthracycline, cytosine, arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukopenia. Cancer 1981; 47: 2779–88.
  • Kreger BE, Craven DE, CarLing PC, McCabe WR. Gram-negative bacteremia. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68: 332–43.
  • Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological ma-lignancies. J Infect Dis 1985; 152: 99–103.
  • Wells CL, Ferrieri P, Weisdorf DJ, Rhame FS. The impor-tance of surveillance stool culture during periods of severe neutropenia. Infect Contr 1987; 8: 317–9.
  • Elting LS, Rubenstein EB, Rolston KVI, Body GP. Outcomes of bacteremia in patients with cancer and neutropenia: obser-vations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247–59.
  • Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 1993; 328: 1323–32.
  • Nomoto K, Yokokura T, Yoshikai Y, Mitsuyama M, Nomoto K. Induction of lethal infection with indigenous Escherichia coli in mice by fluorouracil. Can J Microbiol 1991; 37: 244–7.
  • Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Mane R. Emergence of fluoroquinolon-resistant Escherichia coli at a cancer center. Antimicrobiol Agents Chemother 1994; 38: 681–7.
  • Pizzo PA. Considerations for the prevention of infectious complications in patients with cancer. Rev Infect Dis 1989; 11: 1551–63.
  • Verhoef J, Rozenberg-Arska M, Dekker A. Prevention of infection in the neutropenic patient. Rev Infect Dis 1989; 11: 1545–50.
  • Wells CL, Podzorski RP, Peterson PK, Ramsay NK, Sim-mons RL, Rhame FS. Incidence of trimethoprim-sul-famethoxazole-resistant Enterobacteriaceae among transplant recipients. J Infect Dis 1984; 150: 699–706.
  • Yamagishi T, Sekikawa T, Morita R, Takahashi K, Nishida S. Effect of a Lactobacillus product administration on the anaerobic intestinal flora of aged adults. Jpn J Microbiol 1974; 18: 211–6.
  • Tamura N, Norimoto M, Yoshida K, Hirayama C, Nakai R. Alteration of fecal bacterial flora following oral administra-tion of bifidobacterial preparation. Gastroenterol Jpn 1983; 18: 17–24.
  • Kageyama T, Tomoda T, Nakano Y. The effect of Bifidobac-terium administration in patients with leukemia. Bifidobact Microflora 1984; 3: 29–33.
  • Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a Lactobacillus preparation. Am J Hosp Pharm 1979; 36: 754–7.
  • Hotta M, Sato Y, Iwata S, Yamashita N, Sunakawa K, Oikawa T, et al. Clinical effects of bifidobacterium prepara-tions on pediatric intractable diarrhea. Keio J Med 1987; 36: 298–314.
  • Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp. strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90–7.
  • Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 26: 15–9.
  • Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20: 333–8.
  • Lee YK, Salminen S, Nomoto K, Gorbach SL. Selection and maintenance of probiotic strains. In: Lee YK, ed. Handbook of Probiotics. New York: John Wiley & Sons, Inc., 1999: 23–32.
  • Salminen S, Deighton M, Benno Y, Gorbach SL. Lactic acid bacteria in health and disease. In: Salminen S, von Wright A, eds. Lactic Acid Bacteria; Microbiology and Functional As-pects. New York: Marcel Dekker, Inc, 1998: 211–53.
  • Petts DN. Colistin-oxolinic acid-blood agar. A new selective medium for streptococci. J Clin Microbiol 1984; 19: 4–7.
  • Harmon SM. Collaborative study of an improved method for the enumeration and confirmation of Clostridium perfringens in foods. J Assoc Offic Anal Chem 1976; 59: 606–12.
  • Yuki N, Matsumoto K, Takayama H, Morotomi M, Tanaka R. Isolation and identification of Bifidobacterium from feces of experimental rats: species identification and preparation of improved selective medium. J Intest Microbiol 1999; 12: 97–102.
  • Sonoike K, Mada M, Mutai M. Selective agar medium for counting viable cells of bifidobacteria in fermented milk. J Food Hyg Soc Jap 1986; 27: 238–44.
  • Kok RG, De Waal A, Schut F, Welling GW, Weenk G, Hellingwerf KJ. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Appl Environ Microbiol 1996; 62: 3668–72.
  • Monoclonal antibodies to Bifidobacterium breve strain Yakult and Bifidobacterium bifidum strain Yakult. Under application for a Japanese patent.
  • Kikuchi H, Yajima T. Correlation between water-holding capacity of different types of cellulose in vitro and gastrointes-tinal retention time in vivo of rats. J Sci Food Agr 1992; 60: 139–46.
  • Amanov N, Garib F, Umarov I. Intestinal microbial ecology and its modulation under the influence of immuno depressants (Russian). Antibiotikii Khimioterapiia 1989; 34: 453–7.
  • Hara E, Yazawa K, Nakamura H, Tamura R. Interactions between Bifidobacterium bifidum N4 and Escherichia coli K-2 in their mixed cultures. J Nutr Sci Vitaminol 1978; 24: 569–79.
  • Brocklehurst TF, Lund BM. The influence of pH, tempera-ture and organic acids on the initiation of growth of Yersinia enterocolitica. J Applied Bacteriol 1990; 69: 390–7.
  • El-Zinei MG, De Meyer H, Debevere JM. Growth and survival kinetics of Yersinia enterocolitica IP 383 0:9 as affected by equimolar concentrations of undissociated short-chain organic acids. Intern J Food Microbiol 1997; 34: 233–47.
  • Entani E, Asai M, Tsujihata S, Tsukamoto Y, Ohta M. Antibacterial action of vinegar against food-borne pathogenic bacteria including Escherichia coli 0157:H7. J Food Protect 1998; 61: 953–9.
  • Ostling CE, Lindgren SE. Inhibition of enterobacteria and Listeria growth by lactic, acetic and formic acids. J Appl Bacteriol 1993; 75: 18–24.
  • Imai A, Morishita K. Relationship of volatile components and bacterial flora in mouse caecum. Lab Anim 1983; 17: 45–9.
  • Okada Y, Setoyama H, Matsumoto S, Imaoka A, Nanno M, Kawaguchi M, Umesaki Y. Effects of fecal microorganisms and their chloroform resistant variants derived from mice, rats, and humans on immunological and physiological charac-teristics of the intestines of ex-germfree mice. Infect Immun 1994; 62: 5442–6.
  • Silva AM, Bambirra EA, Oliveira PP, Souza DA, Gomes DA, Vieira EC, Nicoli JR. Protective effect of bifidus milk on the experimental infection with Salmonella enteritidis subsp. ty-phimurium in conventional and gnotobiotic mice. J Applied Microbiol 1999; 86: 331–6.
  • Yasui H, Ohwaki M. Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J Dairy Sci 1990; 74: 1187–95.
  • Yasui H, Nagaoka N, Mike A, Ohwaki M. Detection of Bifidobacterium strains that induce large quantities of IgA. Microbiol Ecol Health Dis 1992; 5: 155–62.
  • Yasui H, Nagaoka N, Hayakawa K. Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer's patch cells with Bifidobacterium breve YIT 4064. Clin Diagnos Lab Immunol 1994; 1: 244–6.
  • Yasui H, Kiyoshima J, Ushijima H. Passive protection against rotavirus-induced diarrhea of mouse pups born to and nursed by dams fed Bifidobacterium breve YIT4064. J Infect Dis 1995; 172: 403–9.
  • Nader de Macias ME, Apella MC, Romero NC, Gonzalez SN, Oliver G. Inhibition of Shigella sonnei by Lactobacillus casei and Lact. acidophilus. J Appl Bacteriol 1992; 73: 407–11.
  • Perdigon G, Nader de Macias ME, Alvarez S, Oliver G, Pesce de Ruiz Holgado AA. Prevention of gastrointestinal infection using immunobiological methods with milk fermented with Lactobacillus casei and Lactobacillus acidophilus. J Dairy Res 1990; 57: 255–64.
  • Nomoto K, Yokokura T, Mitsuyama M, Yoshikai Y, Nomoto K. Prevention of indigenous infection of mice with Escherichia coli by nonspecific immunostimulation. Antimi-crobiol Agent Chemother 1992; 36: 361–7.
  • Salminen S, von Wright A. Current probiotics-safety assured? Microbial Ecol Health Dis 1998; 10: 68–77.
  • Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, et al. Demonstration of safety of probiotics-a review. Int J Food Microbiol 1998; 44: 93–106.
  • Tojo M, Oikawa T, Morikawa Y, Yamashita N, Iwata S, Satoh Y, et al. The effect of Bifidobacterium breve administra-tion on Campylobacter enteritis. Act Paediatr Jpn 1987; 29: 160–7.
  • Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura M. Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial. Arc Dis Child-hood 1997; 76: F101–7.